XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

November 16 – 17, 2015 | Heidelberg, Germany | Innovations in Oncology Workshop

November 16th and 17th 2015, Xentech will attend to Innovations in Oncology Workshop in Heidelberg.   The event bring together scientists and physicians from academics to industry to discuss the latest findings in cancer science and medicine, including our scientists!   Come to see us and discover our latest innovations about PDX used in cancer […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...